Intracerebral Hemorrhage News and Research

RSS

Intracerebral hemorrhage (ICH) is sudden, catastrophic bleeding that occurs in the brain tissue or ventricles. It usually results from damage to blood vessels due to hypertension. Symptoms are often sudden and severe. Loss of consciousness, vomiting, and headache are all common, but milder presentations are also possible, resembling ischemic stroke.

SIRO Clinpharm announces alliance with DreamCIS CRO

SIRO Clinpharm, a Contract Research Organization (CRO) with a presence in India, Western and Central Eastern Europe, and the United States today announced its alliance with DreamCIS Inc., a leading CRO based in Seoul, South Korea.

9 Feb 2010

LPC Pharma Group outsources pharmacovigilance/drug safety operations to APCER Pharma

APCER Pharma announced that LPC Pharma Group is outsourcing its pharmacovigilance/drug safety operations to APCER.

8 Feb 2010

MEND Program: Effective treatment for pediatric obesity

Ground-breaking results from a study to evaluate the effectiveness of the MEND Program (Mind, Exercise, Nutrition, Do it!), a multi-component community-based childhood obesity intervention (www.mendcentral.org), are published today in the US journal Obesity (www.nature.com/oby/journal/v18/n1s/abs/oby2009433a.html). The results coincide with the launch of Michelle Obama's initiative to reduce childhood obesity announced in the State of the Union speech.

2 Feb 2010

Cardene I.V. more effective than intravenous labetalol for BP management in acute stroke patients

EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene® I.V. (nicardipine hydrochloride) is significantly more effective than intravenous labetalol for the management of blood pressure (BP) in stroke patients.

12 Jan 2010

Sanofi Pasteur expands dengue vaccine clinical program in Latin America

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and SNY), announced today the expansion of its dengue vaccine clinical program in Latin America with a new multicenter study in children and adolescent in Mexico, Colombia, Honduras and Puerto Rico. This new multicenter study complements an earlier study in Mexico and an ongoing study in Peru.

10 Dec 2009

ARYx Therapeutics announces operating results for the third quarter of 2009

ARYx Therapeutics, Inc. today reported results of operations and provided a general business update for the third quarter ended September 30, 2009.

12 Nov 2009

USP offers redesigned pharmaceutical standards format to improve key documentation process

To improve key documentation relied upon by the pharmaceutical industry and others, the U.S. Pharmacopeial (USP) Convention announces the release of the redesigned United States Pharmacopeia-National Formulary (USP-NF).

20 Oct 2009

Histostem awarded U.S. patent for isolation of mesenchymal stem cells

Stem Cell Therapy International, Inc. announced that its soon to be subsidiary, Histostem Ltd. of South Korea ("Histostem"), has been awarded U.S. Patent Number 7,582,477 B2, entitled "Method of Isolating and Culturing Mesenchymal Stem Cell Derived from Cryopreserved Umbilical Cord Blood." This patented method is utilized across the company for research, clinical and cosmetic applications.

13 Oct 2009

Positive results from Peregrine's Phase II bavituximab trial for non-small cell lung cancer

Peregrine Pharmaceuticals, Inc. today reported additional positive results in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC). Data previously reported from the initial cohort of 21 patients in the study had indicated that 11 of 17 evaluable patients with locally advanced or metastatic NSCLC achieved an objective tumor response according to RECIST criteria.

5 Oct 2009

Æterna Zentaris announces results of its cetrorelix pamoate clinical development program TQT trial

Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT (TQT) trial, which is part of the cetrorelix pamoate clinical development program in benign prostatic hyperplasia (BPH), met its primary endpoint.

30 Sep 2009

Stem Cell Therapy International merges with Histostem

Stem Cell Therapy International, Inc. is proud to announce the execution of the Reorganization and Stock Purchase Agreement ("the Agreement") with Histostem Co., Ltd., a Korean company ("Histostem" and together with SCII, "the parties").

25 Sep 2009

Patient enrollment completed in Phase II clinical trial of bavituximab

Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in its Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in advanced breast cancer patients.

9 Sep 2009

ERT celebrates a significant milestone: Completes 150Th QT clinical Trial

ERT (Nasdaq: ERES) has celebrated a significant milestone by completing its 150th thorough QT clinical Trial (TET). ERT provides full TET support to the biopharmaceutical industry, including consultation, study design, and provision of ECG equipment to ECG analysis, data processing, management, reconciliation, reporting, quality control and regulatory support.

4 Sep 2009

The 4th annual OPENeCTD forum to be hosted by EXTEDO

EXTEDO, a key eSubmission solutions provider for life sciences firms, today announced that they will be hosting the fourth annual OPENeCTD forum on September 28-29, 2009, in Nice, France.

3 Sep 2009

Interim Phase II data of Cotara reveals signs of efficacy in GBM patients

Peregrine Pharmaceuticals, Inc. today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer.

3 Sep 2009

FDA recommends electronic report formats to strengthen postmarket safety data collection

The U.S. Food and Drug Administration is proposing to amend postmarket safety reporting regulations for three of its centers to require that manufacturers and other facilities subject to current reporting requirements submit their reports in an electronic format.

26 Aug 2009

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).

26 Aug 2009

ECOSOC's agenda should include noncommunicable disease threat in developing countries

"[E]xplicit indicators to measure progress in reducing heart diseases, stroke, diabetes, cancers and chronic respiratory diseases" are missing from the U.N. Economic and Social Council (ECOSOC) agenda as it meets in Geneva this week "to focus on implementing the internationally agreed goals and commitments in regard to public health," and the "omission needs to be urgently addressed if the intent is to have a major impact on reducing poverty by 2015," Ala Alwan, WHO's assistant director-general for Noncommunicable Diseases and Mental Health; George Alleyne, PAHO's director emeritus; and Martin Silink, president of the International Diabetes Federation write in an opinion piece in the Hindu.

8 Jul 2009

Clot-buster boosts survival, decreases disability for deadly subset of stroke

New results from a multicenter study led by Johns Hopkins show that patients who got an experimental clot-busting treatment for a particularly lethal form of stroke were not only dramatically more likely to survive but also continued to shed lingering disabilities six months later.

16 Feb 2009

Women, Latinos face higher brain aneurysm risk

A type of stroke that can strike at any age, and kills one-third of its victims, appears to be more common in women and Mexican-Americans than in non-Hispanic white men, according to a new study from the University of Michigan Stroke Program.

15 Jun 2008